Clinical Trial Update: Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase II study assessing the combination of Fruquintinib and Sintilimab as third-line therapy for metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Metastasis Colorectal Cancer | Phase 2 | Status: UNKNOWN